Vnitr Lek 2016, 62(Suppl 3):68-72

Current and future therapy of acromegaly

Václav Hána
III. interní klinika 1. LF UK a VFN v Praze

Acromegaly is a rare disease caused by overproduction of growth hormone, which significantly worsens quality of life and increases morbidity and mortality of patients. Modern specialized surgery, radiosurgery, radiotherapy and pharmacotherapy substantially improved therapeutical possibilities and the perspective of patients. Current therapeutic modalities enable to create individually tailored therapy for the specific patient and suppress the acromegalic activity. Novel forms of currently used active substances and even conceptually new forms of pharmacotherapy are under preparation and testing (eg. octreotide in capsules, CAM2029, Somatoprim, ATL1103).

Keywords: acromegaly; cabergoline; new drugs; pegvisomant; somatostatin analogs; therapy

Received: August 15, 2016; Accepted: September 1, 2016; Published: June 1, 2016  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Hána V. Current and future therapy of acromegaly. Vnitr Lek. 2016;62(Supplementum 3):68-72.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Hána V, Švancara J, Bandúrová L et al. Registr selárních tumorů - RESET: diagnostika a léčba akromegalie v České a Slovenské republice v 21. století. DMEV2013; 16(4): 219-224. Dostupné z WWW: <http://www.tigis.cz/images/stories/DMEV/2013/04/04_hana.pdf>.
    2. Rajasoorya C, Holdaway IM, Wrightson P et al. Determinants of clinical outcome and survival in acromegaly. Clin Endocrinol (Oxf) 1994; 41(1): 95-102. Go to original source... Go to PubMed...
    3. Katznelson L, Laws jr. ER, Melmed S et al. Acromegaly: an Endocrine society clinical practice guideline. J Clin Endocrinol Metab 2014; 99(11): 3933-3951. Dostupné z DOI: <http://dx.doi.org/10.1210/jc.2014-2700>. Go to original source... Go to PubMed...
    4. Netuka D, Májovský M, Masopust V et al. Intraoperative MRI during endoscopic transsphenoidal surgery of growth hormone-secreting pituitary adenomas. World Neurosurg 2016; 91: 490-496. Dostupné z DOI: <http://dx.doi.org/10.1016/j.wneu.2016.04.094>. Go to original source... Go to PubMed...
    5. Petrossians P, Borges-Martins L, Espinoza C et al. Gross total resection or debulking of pituitary adenomas improves hormonal control of acromegaly by somatostatin analogs. Eur J Endocrinol 2005; 152(1): 61-66. Go to original source... Go to PubMed...
    6. Colao A, Attanasio R, Pivonello R et al. Partial surgical removal of growth hormone-secreting pituitary tumors enhances the response to somatostatin analogs in acromegaly. J Clin Endocrinol Metab 2006; 91(1): 85-92. Go to original source... Go to PubMed...
    7. Rowland NC, Aghi MK. Radiation treatment strategies for acromegaly. Neurosurg Focus 2010; 29(4): E12. Dostupné z DOI: <http://dx.doi.org/10.3171/2010.7.FOCUS10124>. Go to original source... Go to PubMed...
    8. Wattson DA, Tanguturi SK, Spiegel DY et al. Outcomes of proton therapy for patients with functional pituitary adenomas. Int J Radiat Oncol Biol Phys 2014; 90(3): 532-539. Dostupné z DOI: <http://dx.doi.org/10.1016/j.ijrobp.2014.06.068>. Go to original source... Go to PubMed...
    9. Ježková J, Marek J, Hána V et al. Gamma knife radiosurgery for acromegaly-long-term experience. Clin Endocrinol (Oxf) 2006; 64(5): 588-595. Go to original source... Go to PubMed...
    10. Sandret L, Maison P, Chanson P. Place of cabergoline in acromegaly: a meta-analysis. J Clin Endocrinol Metab 2011; 96(5): 1327-1335. Dostupné z DOI: <http://dx.doi.org/10.1210/jc.2010-2443>. Go to original source... Go to PubMed...
    11. Pokrajac A, Frystyk J, Flyvbjerg A et al. Pituitary-independent effect of octreotide on IGF1 generation. Eur J Endocrinol 2009; 160(4): 543-548. Dostupné z DOI: <http://dx.doi.org/10.1530/EJE-08-0822>. Go to original source... Go to PubMed...
    12. Murray RD, Melmed S. A critical analysis of clinically available somatostatin analog formulations for therapy of acromegaly. J Clin Endocrinol Metab 2008; 93(8): 2957-2968. Dostupné z DOI: <http://dx.doi.org/10.1210/jc.2008-0027>. Go to original source... Go to PubMed...
    13. Giustina A, Chanson P, Kleinberg D et al. Expert consensus document: A consensus on the medical treatment of acromegaly. Nature Rev Endocrinol 2014; 10(4): 243-248. Dostupné z DOI: <http://dx.doi.org/10.1038/nrendo.2014.21>. Go to original source... Go to PubMed...
    14. Mercado M, Borges F, Bouterfa H et al. A prospective, multicentre study to investigate the efficacy, safety and tolerability of octreotide LAR in the primary therapy of patients with acromegaly. Clin Endocrinol 2007; 66(6): 859-868. Go to original source... Go to PubMed...
    15. Colao A, Bronstein MD, Freda P et al. Pasireotide versus octreotide in acromegaly: a head-to-head superiority study. J Clin Endocrinol Metab 2014; 99(3): 791-799. Dostupné z DOI: <http://dx.doi.org/10.1210/jc.2013-2480>. Go to original source... Go to PubMed...
    16. Breitschaft A, Hu K, Hermosillo Reséndiz K et al. Management of hyperglycemia associated with pasireotide (SOM230): healthy volunteer study. Diabetes Res Clin Pract 2014; 103(3): 458-465. Dostupné z DOI: <http://dx.doi.org/10.1016/j.diabres.2013.12.011>. Go to original source... Go to PubMed...
    17. Henry RR, Ciaraldi TP, Armstrong D et al. Hyperglycemia associated with pasireotide: results from a mechanistic study in healthy volunteers. J Clin Endocrinol Metab 2013; 98(8): 3446-3453. Dostupné z DOI: <http://dx.doi.org/10.1210/jc.2013-1771>. Go to original source... Go to PubMed...
    18. Van der Lely AJ, Hutson RK, Trainer PJ et al. Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist. Lancet 2001; 358(9295): 1754-1759. Go to original source... Go to PubMed...
    19. van der Lely AJ, Biller BM, Brue T et al. Long-term safety of pegvisomant in patients with acromegaly: comprehensive review of 1288 subjects in ACROSTUDY. J Clin Endocrinol Metab 2012; 97(5): 1589-1597. Dostupné z DOI: <http://dx.doi.org/10.1210/jc.2011-2508>. Go to original source... Go to PubMed...
    20. Neggers SJ, Kopchick JJ, Jørgensen JO et al. Hypothesis: Extra-hepatic acromegaly: a new paradigm? Eur J Endocrinol 2011; 164(1): 11-16. Dostupné z DOI: <http://dx.doi.org/10.1530/EJE-10-0969>. Go to original source... Go to PubMed...
    21. Melmed S. New therapeutic agents for acromegaly. Nat Rev Endocrinol 2016; 12(2): 90-98. Dostupné z DOI: <http://dx.doi.org/10.1038/nrendo.2015.196>. Go to original source... Go to PubMed...
    22. Cuevas-Ramos D, Fleseriu M. Pasireotide: a novel treatment for patients with acromegaly. Drug Des Devel Ther 2016; 10: 227-239. Dostupné z DOI: <http://dx.doi.org/10.2147/DDDT.S77999>. Go to original source... Go to PubMed...
    23. Chieffo C, Cook D, Xiang Q et al. Efficacy and safety of an octreotide implant in the treatment of patients with acromegaly. J Clin Endocrinol Metab 2013; 98(10): 4047-4054. Dostupné z DOI: <http://dx.doi.org/10.1210/jc.2013-2262>. Go to original source... Go to PubMed...
    24. Melmed S, Popovic V, Bidlingmaier M et al. Safety and efficacy of oral octreotide in acromegaly: results of a multicenter phase III trial. J Clin Endocrinol Metab 2015; 100(4): 1699-1708. Dostupné z DOI: <http://dx.doi.org/10.1210/jc.2014-4113>. Go to original source... Go to PubMed...
    25. Afargan M, Janson ET, Gelerman G et al. Novel long-acting somatostatin analog with endocrine selectivity: potent suppression of growth hormone but not of insulin. Endocrinology 2001; 142(1): 477-486. Go to original source... Go to PubMed...
    26. Plöckinger U, Hoffmann U, Geese M et al. DG3173 (somatoprim), a unique somatostatin receptor subtypes 2-, 4- and 5-selective analogue, effectively reduces GH secretion in human GH-secreting pituitary adenomas even in Octreotide non-responsive tumours. Eur J Endocrinol 2012; 166(2): 223-234. Dostupné z DOI: <http://dx.doi.org/10.1530/EJE-11-0737>. Go to original source... Go to PubMed...
    27. Somm E, Bonnet N, Zizzari P et al. Comparative inhibition of the GH/IGF-I axis obtained with either the targeted secretion inhibitor SXN101959 or the somatostatin analog octreotide in growing male rats. Endocrinology 2013; 154(11): 4237-4248. Dostupné z DOI: <http://dx.doi.org/10.1210/en.2013-1427>. Go to original source... Go to PubMed...
    28. Trainer PJ, Newell-Price J, Ayuk J et al. A Phase 2 study of antisense oligonucleotide therapy directed at the GH receptor demonstrates lowering of serum IGF-I in patients with acromegaly. [abstract OR09-1]. Presented at the Endocrine Society's 97th Annual Meeting and Exposition (2015). Dostupné z DOI: <http://dx.doi.org/10.1530/endoabs.37.GP.19.10>. Go to original source...

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.